What is SGP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SGP?

P/E (TTM) is n/a and 52-week range is $17.06 to $32.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SGP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SGP?

The company profile lists net income (TTM) near -$113M, EPS (TTM) near -$3.37 when available from the market-data feed. Figures are informational and may lag live markets.

Where is SpyGlass Pharma, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Aliso Viejo, California, US, 33.5M shares outstanding, ISIN US85220G1094 when available from company profile and filing metadata.

SpyGlass Pharma, Inc.

$SGP

Health Care · Pharmaceuticals

Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

SpyGlass Pharma, Inc.

$SGP

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Employees

65

Website

spyglasspharma.com/

IPO

2026-02-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US85220G1094

Headquarters

Aliso Viejo, California, US

Shares outstanding

33.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

94.67%

Browse other companiesFree AI scores and summaries for more stocks

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Employees

65

Website

spyglasspharma.com/

IPO

2026-02-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)